Barrett Elizabeth A. 4

What Happened
Elizabeth A. Barrett, CEO of UroGen Pharma Ltd. (URGN), was granted 153,195 restricted stock units (RSUs) on January 31, 2026. The grant shows an acquisition at $0.00 because RSUs are compensation awards (no cash purchase). According to the filing, the RSUs are a contingent right to receive ordinary shares once they vest.

Key Details

• Transaction date: 2026-01-31; Form 4 filed: 2026-02-19 (reports the Jan 31, 2026 grant).
• Award size: 153,195 RSUs; reported price: $0.00 (award/grant, code A).
• Vesting: 1/3 of the RSUs vest on each of Jan 31, 2027, Jan 31, 2028 and Jan 31, 2029 (Footnote F2).
• Footnote F1: each RSU represents a contingent right to one ordinary share upon vesting.
• Shares owned after transaction: not disclosed in this Form 4.
• No sale or open‑market purchase — this is a compensation grant, not a trade.

Context
RSUs are a derivative-style compensation award: they do not represent immediately tradable shares until they vest and are settled (typically as shares or net-settled for taxes). Grants can be routine for executive compensation and do not by themselves indicate a buy/sell signal. Note the Form 4 was filed on Feb 19, 2026 for the Jan 31, 2026 grant — Form 4s are generally expected within two business days of the reportable transaction, so investors may want to check the filing history or company disclosures for any explanation.